On September 8th at 11AM EDT, Spectradyne will announce the revolutionary new ARC™ particle analyzer. Based on Spectradyne’s proven Microfluidic Resistive Pulse Sensing (MRPS) technology for measuring size and concentration of biological nanoparticles, the new system adds simultaneous phenotyping by fluorescence. Applications for ARC include:
- Extracellular vesicles (EVs)
- Gene therapy & virus
- Vaccines & nanomedicine
- Biomarkers & diagnostics
Conceptually, the ARC can be thought of as an MRPS instrument for counting and sizing nanoparticles (i.e., Spectradyne’s nCS1) combined with fluorescence-based single-particle phenotyping as in a flow cytometer. In contrast with traditional flow cytometry, which is typically limited to particles larger than 200 nm diameter, the ARC’s MRPS detection method delivers accurate particle size and concentration down to 50 nm diameter. As each particle is counted by MRPS its fluorescence is simultaneously quantified in up to 3 fluorescence channels. Each particle is therefore assigned a size by MRPS, and up to 3 fluorescence intensity values, one for each channel.
Join the 1-hour virtual launch event, which will include:
- Technical overview of ARC system, presented by Spectradyne’s CEO, Jean-Luc Fraikin, Ph.D.
- Instrument demonstration
- A panel discussion featuring industry experts:
Current state and future directions in biological nanoparticle characterization
- Edwin van der Pol (University Medical Center, Amsterdam)
- Ken Witwer (Johns Hopkins University)
- Jennifer Jones (NIH/NCI)
- Audience Q&A with panel
Learn about the new state-of-the-art in biological nanoparticle characterization at this virtual event!